CA
CNCE

Corriente Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Corriente Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-680,000
Closed -$8.6M – 22
2020
Q4 		$8.6M Buy
+680,000
New +$7.75M 2.05% 13

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corriente Advisors's CNCE Position: Q1 2021 in Review

Corriente Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 680,000 shares — an estimated $8.6M sold.

Corriente Advisors first reported a position in CNCE in Q4 2020 and held it in 1 quarter. The position peaked at $8.6M in Q4 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

  • Corriente Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Corriente Advisors sold 680,000 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $8.6M.
  • Corriente Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Corriente Advisors's Concert Pharmaceuticals, Inc. position peaked at $8.6M in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Corriente Advisors's 13F filing for Q1 2021, filed 18 May 2021.